Microsoft moves into genetic-data

  • 5 June 2009

Microsoft Corporation has made a move into genetic data management, following its acquisition of Rosetta Inpharmatics LLC, a subsidiary of pharmaceutical firm Merck & Co.

The Rosetta technology will be used to add genetic and genomic data management abilities to Microsoft’s recently announced Amalga Life Sciences effort.

The agreement calls for Microsoft and Merck to collaborate on software to improve drug discovery and development. Financial details were not disclosed.

Link

Rosetta Inpharmatics LLC

Microsoft Amalga

 

Subscribe To Our Newsletters

Subscribe to our newsletter

Subscribe To Our Newsletter

Related News

Registration opens for Digital Health Summer Schools 2026

Registration opens for Digital Health Summer Schools 2026

Digital Health Summer Schools, the premier NHS IT leadership event taking place on 16-17 July 2026, has opened for registrations.
Ireland hits record €491m health tech VC investment

Ireland hits record €491m health tech VC investment

Irish life sciences and health tech companies set a decade-high record in 2024 raising €491.3 million across 89 VC deals.
MPs call for NHS to rely on UK tech firms instead of US giants

MPs call for NHS to rely on UK tech firms instead of US giants

MPs called for the government to prioritise UK companies for big NHS tech contracts, rather than US giants like Microsoft and Palantir.